[Anti-platelets without a bleeding risk: novel targets and strategies].
Fiche publication
Date publication
janvier 2015
Journal
Biologie aujourd'hui
Auteurs
Membres identifiés du Cancéropôle Est :
Dr GACHET Christian, Dr MANGIN Pierre
Tous les auteurs :
Schaff M, Gachet C, Mangin PH
Lien Pubmed
Résumé
Anti-platelet agents such as aspirin, clopidogrel and antagonists of integrin αIIbβ3 allowed to efficiently reduce morbidity and mortality associated with arterial thrombosis. A major limit of these drugs is that they increase the risk of bleeding. During the last few years, several innovative anti-thrombotic strategies with a potentially low bleeding risk were proposed. These approaches target the collagen receptor glycoprotein (GP) VI, the GPIb/von Willebrand factor axis, the thrombin receptor PAR-1, the activated form of integrin αIIbβ3 or the ADP receptor P2Y1. While an antagonist of PAR-1 was recently marketed, the clinical proofs of the efficiency and safety of the other agents remain to be established. This review evaluates these new anti-platelet approaches toward safer anti-thrombotic therapies.
Mots clés
Animals, Blood Platelets, drug effects, Drugs, Investigational, adverse effects, Fibrinolytic Agents, adverse effects, Hemorrhage, chemically induced, Hemostasis, drug effects, Humans, Molecular Targeted Therapy, methods, Risk Factors
Référence
Biol Aujourdhui. 2015 ;209(3):211-28